Compare ELS & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELS | DVA |
|---|---|---|
| Founded | 1992 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Misc Health and Biotechnology Services |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 14.9B |
| IPO Year | 1994 | 2003 |
| Metric | ELS | DVA |
|---|---|---|
| Price | $61.29 | $190.90 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 4 |
| Target Price | $70.25 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 1.2M | 528.3K |
| Earning Date | 04-21-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.49% | N/A |
| EPS Growth | ★ 2.55 | N/A |
| EPS | 0.56 | ★ 6.86 |
| Revenue | $1,531,382,000.00 | ★ $13,643,069,000.00 |
| Revenue This Year | $3.97 | $3.85 |
| Revenue Next Year | $4.69 | $3.07 |
| P/E Ratio | $107.29 | ★ $26.47 |
| Revenue Growth | 0.34 | ★ 6.46 |
| 52 Week Low | $58.72 | $101.00 |
| 52 Week High | $69.00 | $247.49 |
| Indicator | ELS | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 38.85 | 47.77 |
| Support Level | $61.22 | $145.58 |
| Resistance Level | $63.83 | $202.63 |
| Average True Range (ATR) | 0.93 | 4.47 |
| MACD | -0.33 | 2.25 |
| Stochastic Oscillator | 30.82 | 97.06 |
Equity Lifestyle Properties is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company has a portfolio of 453 properties across the US with a higher concentration in the Sun Belt; 38% of its properties are in Florida, 11% in Arizona, and 10% in California. Equity Lifestyle targets owning properties in attractive retirement destinations. More than 70% of the company's properties are either age-restricted or have an average resident age over 55.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.